Skip to content

Validity of Mediastinal Blood Pool SUV Ratio

Is Mediastinal Blood Pool SUV Ratio Valid in Identification of Malignancy in Comparison to Liver SUV Ratio?

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05258045
Enrollment
55
Registered
2022-02-28
Start date
2022-06-01
Completion date
2023-12-30
Last updated
2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Validity of Blood Pool SUV Ratio in Identification of Malignancy in Case of Diseased Liver

Brief summary

-Validity of blood pool SUV ratio in identification of malignancy in case of diseased liver.

Detailed description

PET/CT is the functional imaging tool that can measure increased glucose metabolism in cancer tissues by using flourine 18 FDG which is FDA approved and used routinely in identification of malignant lesions , staging and restaging of many malignancy like lymphoma, breast cancer, lung cancer and cancer colon. In clinical routine, SUV is often used to determine the glucose metabolism in tumours by 18F-FDG PET/CT. And can be further normalised to SUVs in reference regions resulting in a SUV ratio (SUV ratio).in routine work SUV of the lesion is normalised to SUV of the liver , but this not used if the liver is diseased like as liver cirrhosis or liver metastases , so SUV ratio of lesion to mediastinal blood pool and SUV ratio of the lesion to liver will be measured in correlation to pathology to assess validity of SUV of mediastinal blood pool.

Interventions

RADIATIONF18 FDG

Radioactive material

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL

Inclusion criteria

* This study will include cancer pt who did PET/CT scan who presented to nuclear medicine unit during the period from 2021 until the end of the study.

Exclusion criteria

* Severely ill patient * Pt with glucose level above 200

Design outcomes

Primary

MeasureTime frameDescription
-Validity of blood pool suv ratio in identification of malignancy in case of diseased liver.One yearPET/CT is the functional imaging tool that can measure increased glucose metabolism in cancer tissues by using flourine 18 FDG which is FDA approved and used routinely in identification of malignant lesions , staging and restaging of many maligancy like lymphoma, breast cancer, lung cancer and cancer colon. In clinical routine, SUV is often used to determine the glucose metabolism in tumours by 18F-FDG PET/CT. And can be further normalised to SUVs in reference regions resulting in a SUV ratio (SUV ratio).in routine work SUV of the lesion is normalised to SUV of the liver , but this not used if the liver is diseased like as liver cirrhosis or liver metastases , so SUV ratio of lesion to mediastinal blood pool and SUV ratio of the lesion to liver will be measured in correlation to pathology to assess validity of SUV of mediastinal blood pool.

Contacts

Primary ContactZainab Fathy Mohammed, Resident doctor
zainab.fathy.95@gmail.com01099024404
Backup ContactWaleed Ahmed Diab, Assistant professor
Waleed.diab@aun.edu.eg01004242213

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026